Travere Therapeutics (TVTX) statistics

Analysts' price targets and ratings, ownership, short interest, trading figures and dates for Travere Therapeutics, as the data feed reports them.

Analysts' mean target, 14 analysts
$73.43
43.7% above the price

The 14 analysts reported by the data feed have a mean price target for Travere Therapeutics of $73.43, 43.7% above the $51.10 price (range $62.00–$86.00). 12.90% of the float was sold short as of Oct 30, 2026. Institutions hold 119.1% of the shares and insiders 0.7%. Source: Yahoo Finance, read Nov 17, 2026.

Key facts

Analysts' mean target
$73.43+43.7% vs price
Analysts
14
Short interest
12.90%of float, Oct 30, 2026
Short ratio
4.65 days
Institutions
119.1%
Insiders
0.68%
Beta
1.12

Figures read . Source: Yahoo Finance (quoteSummary: key statistics, financial data, recommendation trend, major holders, insider purchases, calendar events). Analysts' targets and ratings, ownership and short interest are the data feed's figures and can lag the filings and exchange reports they come from. Figures, not advice.

Analysts' consensus as reported by the data feed

14 analysts covering Travere Therapeutics, as the data feed counts them. Price targets and ratings are other people's estimates — not facts about the company, and not advice. Distances are from the latest price the feed gave with these figures, $51.10.

Analysts' price targets for Travere Therapeutics
Mean price target$73.4343.7% above the price (+43.7%)
Median price target$73.5043.8% above the price (+43.8%)
Highest target$86.0068.3% above the price (+68.3%)
Lowest target$62.0021.3% above the price (+21.3%)
Analysts with a target14

Ratings this month · 15 analysts

Strong buy 2(13%)Buy 12(80%)Hold 1(7%)
Analysts' ratings of Travere Therapeutics this month, by rating
RatingAnalystsShare
Strong buy213%
Buy1280%
Hold17%
Sell00%
Strong sell00%

The feed averages these to 1.27 on its scale of 1 (strong buy) to 5 (strong sell), which it labels “strong buy”.

Who owns Travere Therapeutics

Ownership of Travere Therapeutics
Held by institutions119.1%466 institutions; percent of shares outstanding
Held by institutions, of the float119.9%
Held by insiders0.68%percent of shares outstanding
Shares outstanding95.99M
Float94.95Mshares available to trade
Insiders' net purchases, six months+32.58K15 purchases (324.7K shares), 7 sales (292.13K shares)

Percentages are of shares outstanding unless the row says float. Insiders' net purchases are shares bought minus shares sold by insiders, as the data feed totals their reported trades.

Short interest as reported by the data feed

Shares sold short and not yet covered, as of Oct 30, 2026. Short interest is counted twice a month, so this is not today's figure.

Short interest in Travere Therapeutics
Shares short9.56Mas of Oct 30, 2026
Percent of float12.90%shares short ÷ float
Percent of shares outstanding9.96%shares short ÷ shares outstanding
Short ratio (days to cover)4.65shares short ÷ average daily volume

Travere Therapeutics short interest from FINRA, with its history

Trading figures

Trading figures for Travere Therapeutics
Beta1.12movement against the market; 1 moves with it
52-week high$68.73
52-week low$22.59
Average volume, 3 months1.81Mshares a day
Average volume, 10 days2.24Mshares a day

Questions and answers

What is the analysts' price target for Travere Therapeutics (TVTX)?

As reported by the data feed, the mean price target of the 14 analysts covering Travere Therapeutics is $73.43, 43.7% above the latest price of $51.10. The highest target is $86.00 and the lowest $62.00. Targets are analysts' estimates, not facts about the company and not advice.

How do analysts rate Travere Therapeutics stock?

Of the 15 ratings the data feed reports for the current month, 2 are strong buy, 12 buy, 1 hold, 0 sell and 0 strong sell.

How many Travere Therapeutics shares are sold short?

As reported by the data feed, 9.56M shares were sold short, 12.90% of the float as of Oct 30, 2026. At the average daily volume that is 4.65 days to cover. Short interest is reported twice a month; it is not today's figure.

Who owns Travere Therapeutics stock?

As reported by the data feed, institutions hold 119.1% of the shares (466 institutions) and insiders 0.7%. There are 95.99M shares outstanding, of which 94.95M are in the float.

How much does Travere Therapeutics stock move with the market?

Its beta, as reported by the data feed, is 1.12: a beta above 1 means the share has tended to move more than the market, below 1 less. Over the past 52 weeks it traded between $22.59 and $68.73.

Cite this page

Funkfolio, “Travere Therapeutics (TVTX) statistics and analyst targets”, data as of 17 November 2026. https://funkfolio.com/stock/TVTX/statistics

Underlying data: Yahoo Finance.